Compare Moderna, Inc. (MRNA) vs Snap On Incorporated (SNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Snap On Incorporated — how do they compare? Moderna, Inc. trades at $135.93 (market cap $56.02B), while Snap On Incorporated trades at $377.53 (market cap $19.65B). The key difference: Moderna, Inc. is far larger — about 2.9× Snap On Incorporated's market cap, and Snap On Incorporated pays a 2.57% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | SNA | |
|---|---|---|
Market Cap | $56.02B | $19.65B |
Sector | Health | Technology |
52-Week High | $174.38 | $419.31 |
52-Week Low | $22.36 | $324.16 |
Enterprise Value | $52.17B | $19.28B |
Dividend Yield | — | 2.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, but maintains a bullish technical signal with support at $138 and resistance at $145. Recent positive phase 3 cancer vaccine trial results have driven significant stock appreciation, though financials show declining revenue and negative net income margins. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending.
The outlook is mixed; promising clinical developments in oncology offer long-term growth potential, but high valuation multiples and persistent losses pose risks. Analyst consensus is cautious with a $90.08 price target below the current price, reflecting concerns over profitability and competitive pressures in the mRNA therapeutics space.
Snap-On Incorporated (SNA) trades at $379.88, down 0.81% with bearish technical signals but strong fundamentals. The stock shows solid profitability with 19.6% net margins and 17.58% ROE, supported by consistent earnings beats in recent quarters. Recent institutional activity shows mixed positioning while analyst consensus remains bullish with a $473 price target representing 24.5% upside potential.
SNA presents a compelling value opportunity with premium valuation metrics balanced by robust cash flow generation and dividend stability. Key risks include integration challenges from recent acquisitions and potential margin pressure from rising costs. The stock's current technical weakness may offer entry points for long-term investors seeking quality industrial exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →
